ArriVent BioPharma, Inc. shareholders approved Auditor Ratification at the 2026-06-18 meeting.
“2. Auditor Ratification Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 33,411,773 829 6,191 0”
ArriVent BioPharma, Inc. — fact timeline
Source-grounded facts extracted from ArriVent BioPharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ArriVent BioPharma, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.
“1. Election of Directors Nominee Shares Voted For Shares Voted to Withhold Authority Broker Non-votes James Healy, M.D., Ph.D. 18,058,285 11,527,650 3,832,858 John Hohneker, M.D. 28,043,164 1,542,771 3,832,858 Stuart Lutzker, M.D., Ph.D. 29,495,923 90,012 3,832,858”
ArriVent BioPharma, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively..
“Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively.”
ArriVent BioPharma, Inc. reported the year ended December 31, 2025 results: net income Net loss was $166.3 million.
“ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.”
Merdad Parsey was appointed as Director at ArriVent BioPharma, Inc..
“the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board”
Carl L. Gordon departed as Director at ArriVent BioPharma, Inc..
“On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025”
ArriVent BioPharma, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“On March 11, 2025, the Audit Committee appointed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”
ArriVent BioPharma, Inc. dismissed KPMG LLP as its auditor.
“On March 11, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of ArriVent BioPharma, Inc. (the “Company”) approved the dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.”
Kristine Peterson was appointed as Director at ArriVent BioPharma, Inc..
“On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”).”
John Hohneker, M.D. was appointed as Class II Director at ArriVent BioPharma, Inc..
“On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”).”
ArriVent BioPharma, Inc. reported first quarter ended March 31, 2024 results: net income $17.4 million.
“Net loss was $17.4 million and $12.2 million for the quarters ended March 31, 2024 and 2023, respectively.”
Kristine Peterson was appointed as Director at ArriVent BioPharma, Inc..
“On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately”
ArriVent BioPharma, Inc. reported the full year ended December 31, 2023 results: net income Net loss was $69.3 million.
“ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.”
ArriVent BioPharma, Inc.: Adopted amended and restated bylaws in connection with closing of IPO (effective 2024-01-30).
“The Company also adopted its amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.”
ArriVent BioPharma, Inc.: Amended and restated certificate of incorporation filed in connection with closing of IPO (effective 2024-01-30).
“On January 30, 2024, ArriVent BioPharma, Inc. (the “Company”) filed its amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of its initial public offering (the “IPO”) of common stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.